Commonwealth Equity Services LLC lowered its position in shares of Boston Scientific Co. (NYSE:BSX – Free Report) by 1.9% in the first quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 141,820 shares of the medical equipment provider’s stock after selling 2,761 shares during the quarter. Commonwealth Equity Services LLC’s holdings in Boston Scientific were worth $7,095,000 at the end of the most recent reporting period.
A number of other large investors have also recently bought and sold shares of the company. Clearstead Advisors LLC boosted its position in Boston Scientific by 29.6% during the 1st quarter. Clearstead Advisors LLC now owns 854 shares of the medical equipment provider’s stock worth $43,000 after acquiring an additional 195 shares during the last quarter. BerganKDV Wealth Management LLC boosted its position in Boston Scientific by 44.3% during the 1st quarter. BerganKDV Wealth Management LLC now owns 658 shares of the medical equipment provider’s stock worth $33,000 after acquiring an additional 202 shares during the last quarter. Forum Financial Management LP boosted its holdings in shares of Boston Scientific by 1.8% in the 1st quarter. Forum Financial Management LP now owns 11,903 shares of the medical equipment provider’s stock valued at $596,000 after buying an additional 205 shares during the last quarter. Dubuque Bank & Trust Co. boosted its holdings in shares of Boston Scientific by 4.3% in the 1st quarter. Dubuque Bank & Trust Co. now owns 5,112 shares of the medical equipment provider’s stock valued at $256,000 after buying an additional 209 shares during the last quarter. Finally, Relyea Zuckerberg Hanson LLC boosted its holdings in shares of Boston Scientific by 1.5% in the 1st quarter. Relyea Zuckerberg Hanson LLC now owns 15,306 shares of the medical equipment provider’s stock valued at $766,000 after buying an additional 223 shares during the last quarter. Institutional investors and hedge funds own 89.11% of the company’s stock.
Analysts Set New Price Targets
Several equities research analysts have recently commented on BSX shares. Raymond James increased their price objective on Boston Scientific from $60.00 to $61.00 in a report on Friday, July 28th. Morgan Stanley started coverage on Boston Scientific in a report on Tuesday, May 30th. They issued an “overweight” rating and a $58.00 price objective for the company. Robert W. Baird assumed coverage on Boston Scientific in a research note on Tuesday, July 18th. They issued an “outperform” rating and a $59.00 price target on the stock. CL King assumed coverage on Boston Scientific in a report on Friday, June 30th. They set a “buy” rating and a $64.00 price target for the company. Finally, Royal Bank of Canada reaffirmed an “outperform” rating and set a $58.00 price target on shares of Boston Scientific in a report on Monday. Two investment analysts have rated the stock with a hold rating, fourteen have given a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, Boston Scientific has a consensus rating of “Moderate Buy” and a consensus target price of $58.50.
Insider Activity
In other news, EVP Arthur C. Butcher sold 6,600 shares of the business’s stock in a transaction that occurred on Monday, August 21st. The shares were sold at an average price of $50.40, for a total value of $332,640.00. Following the completion of the transaction, the executive vice president now directly owns 11,396 shares in the company, valued at approximately $574,358.40. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. In related news, EVP Wendy Carruthers sold 11,671 shares of the company’s stock in a transaction that occurred on Thursday, June 15th. The shares were sold at an average price of $53.24, for a total transaction of $621,364.04. Following the completion of the transaction, the executive vice president now directly owns 72,847 shares in the company, valued at approximately $3,878,374.28. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, EVP Arthur C. Butcher sold 6,600 shares of the company’s stock in a transaction that occurred on Monday, August 21st. The stock was sold at an average price of $50.40, for a total transaction of $332,640.00. Following the transaction, the executive vice president now owns 11,396 shares of the company’s stock, valued at $574,358.40. The disclosure for this sale can be found here. In the last ninety days, insiders sold 95,110 shares of company stock worth $4,934,535. 0.53% of the stock is currently owned by corporate insiders.
Boston Scientific Price Performance
Shares of Boston Scientific stock opened at $54.26 on Thursday. Boston Scientific Co. has a twelve month low of $37.74 and a twelve month high of $54.99. The company has a quick ratio of 0.80, a current ratio of 1.29 and a debt-to-equity ratio of 0.46. The company has a 50-day simple moving average of $52.24 and a two-hundred day simple moving average of $51.02. The stock has a market capitalization of $79.45 billion, a price-to-earnings ratio of 90.43, a price-to-earnings-growth ratio of 2.11 and a beta of 0.79.
Boston Scientific (NYSE:BSX – Get Free Report) last issued its quarterly earnings data on Thursday, July 27th. The medical equipment provider reported $0.53 earnings per share for the quarter, topping the consensus estimate of $0.49 by $0.04. Boston Scientific had a net margin of 6.81% and a return on equity of 15.16%. The business had revenue of $3.60 billion during the quarter, compared to analysts’ expectations of $3.50 billion. During the same quarter in the previous year, the company earned $0.44 EPS. The business’s revenue was up 10.9% on a year-over-year basis. Analysts forecast that Boston Scientific Co. will post 1.99 EPS for the current year.
Boston Scientific Company Profile
Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through MedSurg and Cardiovascular segments. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions; devices to treat various urological and pelvic conditions; implantable cardioverter and implantable cardiac resynchronization therapy defibrillators; pacemakers and implantable cardiac resynchronization therapy pacemakers; and remote patient management systems.
Featured Articles
- Five stocks we like better than Boston Scientific
- How to Invest in Toy Stocks
- Why Ambarella’s 20% Decline is a Strong Signal for New Investment
- How Investors Can Identify and Successfully Trade Gap-Up Stocks
- Why Analysts Love These 2 Car Sales Platforms, And Avoid Dealers
- When to Sell a Stock for Profit or Loss
- A Significant Reversal is in Sight for These 5 Med Tech Companies
Receive News & Ratings for Boston Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Boston Scientific and related companies with MarketBeat.com's FREE daily email newsletter.
